NO20050526L - Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling - Google Patents

Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling

Info

Publication number
NO20050526L
NO20050526L NO20050526A NO20050526A NO20050526L NO 20050526 L NO20050526 L NO 20050526L NO 20050526 A NO20050526 A NO 20050526A NO 20050526 A NO20050526 A NO 20050526A NO 20050526 L NO20050526 L NO 20050526L
Authority
NO
Norway
Prior art keywords
ppar
agonist
treatment
weight gain
alfa
Prior art date
Application number
NO20050526A
Other languages
English (en)
Norwegian (no)
Inventor
Jean-Louis Junien
Alan Dunlap Edgar
Evelyne Chaput
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02291994A external-priority patent/EP1388351A1/fr
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of NO20050526L publication Critical patent/NO20050526L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050526A 2002-08-08 2005-01-31 Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling NO20050526L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291994A EP1388351A1 (fr) 2002-08-08 2002-08-08 Utilisation d'un fibrate pour le traitement d'obesité associée au traitement par le rosiglitazone
EP02292830A EP1388352A1 (fr) 2002-08-08 2002-11-14 Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
PCT/EP2003/008756 WO2004018041A1 (fr) 2002-08-08 2003-08-06 Utilisation d'un agoniste de ppar alpha pour traiter une prise de poids liee a un traitement par les agonistes de ppar gamma

Publications (1)

Publication Number Publication Date
NO20050526L true NO20050526L (no) 2005-03-02

Family

ID=30445152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050526A NO20050526L (no) 2002-08-08 2005-01-31 Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling

Country Status (10)

Country Link
US (2) US20040110799A1 (fr)
EP (2) EP1388352A1 (fr)
JP (1) JP4588448B2 (fr)
CN (1) CN1674959A (fr)
AT (1) ATE536913T1 (fr)
AU (1) AU2003260380B2 (fr)
CA (1) CA2493747A1 (fr)
ES (1) ES2379165T3 (fr)
NO (1) NO20050526L (fr)
WO (1) WO2004018041A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
ES2137915T3 (es) 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
EP0497894A4 (en) 1989-10-25 1993-03-31 The Salk Institute For Biological Studies Receptor infection assay
EP0441483A3 (en) 1990-01-16 1992-11-19 Baylor College Of Medicine Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
AU655943B2 (en) 1990-09-21 1995-01-19 Salk Institute For Biological Studies, The Functional antagonism between proto-oncoprotein c-jun and hormone receptors
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
AU666348B2 (en) 1991-12-06 1996-02-08 Salk Institute For Biological Studies, The Multimeric forms of members of the steroid/thyroid superfamily of receptors
CA2135644C (fr) 1992-05-14 2009-01-27 Elisabetta Vegeto Recepteurs steroidiens mutants, modes d'utilisation et declencheur moleculaire servant a la therapie genique
CA2160135A1 (fr) 1993-04-07 1994-10-13 Donald P. Mcdonnell Methode pour depister les agonistes de recepteurs
US5506102A (en) 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
CA2180271A1 (fr) 1993-12-30 1995-07-06 Ronald M. Evans Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
EP0888278B1 (fr) 1996-02-02 2003-07-23 Merck & Co., Inc. Agents anti-diabete
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
JP2002515865A (ja) 1996-02-02 2002-05-28 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
ES2194179T3 (es) 1996-02-02 2003-11-16 Merck & Co Inc Derivados heterociclicos como agentes antidiabeticos y antiobesidad.
ES2241036T3 (es) 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
TW438784B (en) 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6329403B1 (en) * 1998-06-30 2001-12-11 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
MXPA02010316A (es) 2000-04-19 2005-04-19 Borody Thomas J Terapia novedosa para los trastornos asociados con la hiperlipidemia.
CA2415742A1 (fr) * 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
EP1320362B1 (fr) * 2000-09-20 2011-08-31 Jagotec AG Microparticules de fibrate stabilisees
WO2002028857A1 (fr) * 2000-10-05 2002-04-11 Dr. Reddy's Research Foundation Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法

Also Published As

Publication number Publication date
EP1388352A1 (fr) 2004-02-11
WO2004018041A1 (fr) 2004-03-04
US20090099238A1 (en) 2009-04-16
CN1674959A (zh) 2005-09-28
EP1526894B1 (fr) 2011-12-14
ATE536913T1 (de) 2011-12-15
AU2003260380A1 (en) 2004-03-11
JP4588448B2 (ja) 2010-12-01
EP1526894A1 (fr) 2005-05-04
CA2493747A1 (fr) 2004-03-04
US20040110799A1 (en) 2004-06-10
JP2005539033A (ja) 2005-12-22
AU2003260380B2 (en) 2008-11-06
ES2379165T3 (es) 2012-04-23

Similar Documents

Publication Publication Date Title
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20051692L (no) Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt
DE50310516D1 (de) Fredericamycin-derivate
PL374865A1 (en) Treatment of tnf alpha related disorders
GB0318447D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
EP1490044A4 (fr) Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
DK1610864T3 (da) Elektromagnetisk stimulering af patienter med osteoporose
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
NO20050526L (no) Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
NO20051468L (no) Behandling av ikke-allergisk rhinitt med selektive fosfodiesterase-4-inhibitorer
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
HUP0101350A2 (hu) Generalizált szorongásos rendellenesség kezelése paroxetinnel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application